文献速递淋巴瘤

经典霍奇金淋巴瘤初始化疗后的死因特异性死亡率:2000-2016年基于人群的队列研究

Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.
PubMed 文献 · J Clin Oncol · 2020-09-18

研究发现,尽管治疗模式演变,患者仍面临多种非淋巴瘤死亡原因的风险增加,尤其是晚期患者非癌标化死亡比(SMR)升高2.4倍。心脏疾病、感染、间质性肺病和药物不良事件是主要超额死亡原因,且部分风险在治疗后1年内即显著升高。

要点

  • cHL患者非癌死亡风险显著高于一般人群,晚期患者SMR为2.4,早期为1.6。
  • 间质性肺病、感染和药物不良事件的SMR在cHL诊断后1年内即显著升高。
  • 60-74岁晚期cHL患者心脏疾病、间质性肺病、感染、不良事件和实体瘤死亡超额尤为突出。

核心结论

  • 尽管cHL治疗不断演变,患者仍面临多种潜在可预防的非淋巴瘤死亡风险增加。
  • 监测、早期干预和cHL治疗优化可能改善患者生存,尤其在高危亚组。

主要发现

  • 共观察到3380例死亡,其中1321例(39%)非淋巴瘤相关。
  • 晚期cHL非癌SMR为2.4(95%CI 2.2-2.6;观察值559;EAR 61.6),早期为1.6(95%CI 1.4-1.7;观察值473;EAR 18.2)。
  • 晚期cHL非癌死亡EAR较高的原因包括心脏病(EAR 15.1;SMR 2.1)、感染(EAR 10.6;SMR 3.9)、间质性肺病(EAR 9.7;SMR 22.1)和药物不良事件(EAR 7.4;SMR 5.0)。
  • 早期cHL非癌死亡EAR较高的原因包括心脏病(EAR 6.6;SMR 1.7)、间质性肺病(EAR 3.7;SMR 13.1)和感染(EAR 3.1;SMR 2.2)。
  • 间质性肺病、感染和药物不良事件的SMR在cHL诊断后1年内显著升高。

临床怎么用

  • 对cHL幸存者,尤其是老年晚期患者,应加强心脏疾病、感染、间质性肺病和药物不良事件的监测与早期干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mortality for patients with classical Hodgkin lymphoma (cHL) treated during an era characterized in the United States by widespread use of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radiotherapy is not well understood. PATIENTS AND METHODS: We identified 20,007 individuals diagnosed with stage I/II (early) or III/IV (advanced) cHL between age 20 and 74 years treated with initial chemotherapy in US population-based cancer registries during 2000-2015 (follow-up through 2016). We used standardized mortality ratios (SMRs) to compare cause-specific relative mortality risk following cHL to that expected in the general population and estimated excess absolute risks (EARs; per 10,000 patient-years) to quantify disease-specific death burden. RESULTS: We identified 3,380 deaths in the cHL cohort, including 1,321 (39%) not attributed to lymphoma. Overall, noncancer SMRs were increased 2.4-fold (95% CI, 2.2 to 2.6; observed, 559; EAR, 61.6) and 1.6-fold (95% CI, 1.4 to 1.7; observed, 473; EAR, 18.2) for advanced- and early-stage cHL, respectively, compared with the general US population. SMRs and EARs differed substantially by cause of death and cHL stage. Among the highest EARs for noncancer causes of death were those for heart disease (EAR, 15.1; SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), and adverse events (AEs) related to medications/drugs (EAR, 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR, 13.1), and infections (EAR, 3.1; SMR, 2.2) after early-stage cHL. Strikingly elevated SMRs for ILD, infections, and AEs were observed < 1 year after cHL. Individuals age 60-74 years with advanced-stage cHL experienced a disproportionate excess of deaths as a result of heart disease, ILD, infections, AEs, and solid tumors. CONCLUSION: Despite evolving cHL treatment approaches, patients continue to face increased nonlymphoma mortality risks from multiple, potentially preventable causes. Surveillance, early interventions, and cHL treatment refinements may favorably affect patient longevity, particularly among high-risk subgroups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dores GM, Curtis RE, Dalal NH, et al. Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016. J Clin Oncol. 2020. PMID: 32946352. doi:10.1200/JCO.20.00264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。